149.56 +0.56 (0.37%)
After hours: 4:26PM EST
|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||148.78 - 151.47|
|52 Week Range||98.35 - 167.35|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||593.63|
|Earnings Date||Feb 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||160.14|
Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.
Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.
The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.
Penumbra Inc NYSE:PENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for PEN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding PEN totaled $4.44 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to help shape the future of investing tools? Participate in a short research study and receive a 6-month subscription to the award winning Simply Wall St research tool (valued Read More...
ALAMEDA, Calif. , Jan. 30, 2019 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2018 after ...
The development is likely to boost Varian Medical's (VAR) Proton business that declined 12% year over year in the last reported quarter.
ALAMEDA, Calif., Jan. 18, 2019 /PRNewswire/ -- Penumbra, Inc. (PEN) today announced that two new Board members were appointed to its Board of Directors (the "Board") on January 17, 2019. Ms. Janet Leeds was appointed to the Board as a Class I director, effective immediately, and Ms. Surbhi Sarna was appointed to the Board as a Class II director, effective July 1, 2019. "We are thrilled to welcome Janet and Surbhi to our Board. Both of these individuals will bring added experience, perspective, and capability to our Board of Directors which will be invaluable as we continue to grow and scale our company.
Surmodics (SRDX) is gaining strength from the In Vitro Diagnostics (IVD) unit. The segment is a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.
NEW YORK, Jan. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Masimo (MASI) issues guidance for 2019. It anticipates witnessing strong contribution from its core product revenue segment.